Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Long-term evaluation of cross-sex hormone treatment in transsexual persons.

Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, T'Sjoen G.

J Sex Med. 2012 Oct;9(10):2641-51. doi: 10.1111/j.1743-6109.2012.02876.x. Epub 2012 Aug 20.

PMID:
22906135
2.

Conjectures concerning cross-sex hormone treatment of aging transsexual persons.

Gooren L, Lips P.

J Sex Med. 2014 Aug;11(8):2012-9. doi: 10.1111/jsm.12563. Epub 2014 Apr 29.

PMID:
24775178
3.

Body composition, volumetric and areal bone parameters in male-to-female transsexual persons.

Lapauw B, Taes Y, Simoens S, Van Caenegem E, Weyers S, Goemaere S, Toye K, Kaufman JM, T'Sjoen GG.

Bone. 2008 Dec;43(6):1016-21. doi: 10.1016/j.bone.2008.09.001. Epub 2008 Sep 16.

PMID:
18835591
4.

Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy.

Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van de Peer F, Toye K, Kaufman JM, T'Sjoen G.

J Clin Endocrinol Metab. 2012 Jul;97(7):2503-11. doi: 10.1210/jc.2012-1187. Epub 2012 May 7.

PMID:
22564669
5.

Low bone mass is prevalent in male-to-female transsexual persons before the start of cross-sex hormonal therapy and gonadectomy.

Van Caenegem E, Taes Y, Wierckx K, Vandewalle S, Toye K, Kaufman JM, Schreiner T, Haraldsen I, T'Sjoen G.

Bone. 2013 May;54(1):92-7. doi: 10.1016/j.bone.2013.01.039. Epub 2013 Jan 28.

PMID:
23369987
6.

Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Gooren LJ, van Trotsenburg MA, Giltay EJ, van Diest PJ.

J Sex Med. 2013 Dec;10(12):3129-34. doi: 10.1111/jsm.12319. Epub 2013 Sep 9.

PMID:
24010586
7.

Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.

Wierckx K, Elaut E, Declercq E, Heylens G, De Cuypere G, Taes Y, Kaufman JM, T'Sjoen G.

Eur J Endocrinol. 2013 Sep 13;169(4):471-8. doi: 10.1530/EJE-13-0493. Print 2013 Oct.

8.

Sexual desire in trans persons: associations with sex reassignment treatment.

Wierckx K, Elaut E, Van Hoorde B, Heylens G, De Cuypere G, Monstrey S, Weyers S, Hoebeke P, T'Sjoen G.

J Sex Med. 2014 Jan;11(1):107-18. doi: 10.1111/jsm.12365. Epub 2013 Oct 24.

PMID:
24165564
9.

Quality of life and sexual health after sex reassignment surgery in transsexual men.

Wierckx K, Van Caenegem E, Elaut E, Dedecker D, Van de Peer F, Toye K, Weyers S, Hoebeke P, Monstrey S, De Cuypere G, T'Sjoen G.

J Sex Med. 2011 Dec;8(12):3379-88. doi: 10.1111/j.1743-6109.2011.02348.x. Epub 2011 Jun 23.

PMID:
21699661
10.

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.

Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, Spack NP, Tangpricha V, Montori VM; Endocrine Society.

J Clin Endocrinol Metab. 2009 Sep;94(9):3132-54. doi: 10.1210/jc.2009-0345. Epub 2009 Jun 9.

PMID:
19509099
11.

Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.

Smith KP, Madison CM, Milne NM.

Pharmacotherapy. 2014 Dec;34(12):1282-97. doi: 10.1002/phar.1487. Epub 2014 Sep 15. Review.

PMID:
25220381
12.

Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.

Moore E, Wisniewski A, Dobs A.

J Clin Endocrinol Metab. 2003 Aug;88(8):3467-73. Review.

PMID:
12915619
13.

Five new cases of breast cancer in transsexual persons.

Gooren L, Bowers M, Lips P, Konings IR.

Andrologia. 2015 Dec;47(10):1202-5. doi: 10.1111/and.12399. Epub 2015 Jan 22.

PMID:
25611459
14.

People with gender dysphoria who self-prescribe cross-sex hormones: prevalence, sources, and side effects knowledge.

Mepham N, Bouman WP, Arcelus J, Hayter M, Wylie KR.

J Sex Med. 2014 Dec;11(12):2995-3001. doi: 10.1111/jsm.12691. Epub 2014 Sep 11.

PMID:
25213018
15.

Transsexual Voice Questionnaire for Male-to-female Brazilian Transsexual People.

Schwarz K, Fontanari AMV, Mueller A, Costa AB, Soll B, da Silva DC, Cielo CA, Kuhl G, Spritzer PM, Schneider MA, Dorfmann ME, Lobato MIR.

J Voice. 2017 Jan;31(1):120.e15-120.e20. doi: 10.1016/j.jvoice.2016.02.012. Epub 2016 Apr 14.

PMID:
27146028
16.

Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.

Gooren LJ, Wierckx K, Giltay EJ.

Eur J Endocrinol. 2014 Jun;170(6):809-19. doi: 10.1530/EJE-14-0011. Epub 2014 Mar 10. Review.

17.

A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.

Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ.

Eur J Endocrinol. 2011 Apr;164(4):635-42. doi: 10.1530/EJE-10-1038. Epub 2011 Jan 25.

18.

Short- and long-term clinical skin effects of testosterone treatment in trans men.

Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, Kaufman JM, T'Sjoen G.

J Sex Med. 2014 Jan;11(1):222-9. doi: 10.1111/jsm.12366. Epub 2013 Oct 31.

PMID:
24344810
19.

[Morbidity in transsexual patients with cross-gender hormone self-treatment].

Becerra Fernández A, de Luis Román DA, Piédrola Maroto G.

Med Clin (Barc). 1999 Oct 23;113(13):484-7. Spanish.

PMID:
10604171
20.

Long-term evaluation of donor-site morbidity after radial forearm flap phalloplasty for transsexual men.

Van Caenegem E, Verhaeghe E, Taes Y, Wierckx K, Toye K, Goemaere S, Zmierczak HG, Hoebeke P, Monstrey S, T'Sjoen G.

J Sex Med. 2013 Jun;10(6):1644-51. doi: 10.1111/jsm.12121. Epub 2013 Mar 27.

PMID:
23534878

Supplemental Content

Support Center